论文部分内容阅读
寻求ＨＣＶ基因免疫的最佳动物实验方法，探讨不同处理因素对基因重组体ｐＣＤ－ＨＣＶ１诱发小鼠产生抗体的影响。方法：用分子生物学技术构建丙型肝炎病毒基因重组体ｐＣＤ－ＨＣＶ１，采用不同免疫次数、途径、剂量和不同处理方法免疫Ｂａｌｂ／ｃ小鼠。结果：重组体ｐＣＤ－ＨＣＶ１经肌肉１、２、３和４次免疫小鼠后（１００μｇ／只，ｎ＝１２），抗体水平分别为０１８３±０００６、０４２８±００５、０７０７±００８和０７７３±００７（Ａ值，下同）。其中４次免疫小鼠的抗体水平最高；ｐＣＤ－ＨＣＶ经灌胃、腹腔注射、皮下注射和肌肉注射（１００μｇ）不同途径分别免疫小鼠（ｎ＝６）抗体水平依次为０１３８±０００５、０１７８±００７、０２３３±００８和０６９１±００５，ＳＮＫ统计显示，肌肉注射途径与其他３种注射途径相比，抗体水平有显著差异（Ｐ＜０００１）；以不同剂量（１０、５０和１００μｇ）分别免疫小鼠（ｎ＝８），抗体水平依次为０１１±００９、０３３±００４和０７０±００７；各组间差异有显著性意义（Ｐ＜００１）；用普鲁卡因１００μｇ（０．４ｍｇ）肌肉注射小鼠２４ｈ后，再肌肉、皮下注射ｐＣＤ－ＨＣ?
The aim of this study was to investigate the effects of different treatment factors on antibody production in mice induced by pCD-HCV1. Methods: The recombinant plasmid pCD-HCV1 of hepatitis C virus was constructed by molecular biology techniques. Balb / c mice were immunized with different immunization times, route, dosage and different treatments. Results: After the mice were immunized with recombinant pCD-HCV1 for 1, 2, 3 and 4 times (100μg / mouse, n = 12), their antibody levels were 0183 ± 0006,0428 ± 005 , 0707 ± 008 and 0773 ± 007 (A value, the same below). The antibody level of the four immunized mice was the highest. The antibody levels of pCD-HCV immunized with different routes of gavage, intraperitoneal injection, subcutaneous injection and intramuscular injection (100μg) were 0138 ± 0 005, 0178 ± 007, 0233 ± 008 and 0691 ± 005, SNK statistics showed that the intramuscular injection route compared with the other three injection routes, antibody levels were significantly different (P < 0 001). The mice were immunized with different dosages (10, 50 and 100 μg) respectively (n = 8). The antibody levels were 011 ± 009,033 ± 004 and 070 ± 0 07; There was significant difference among the groups (P <001). After intramuscular injection of procaine 100 μg (0.4 mg) for 24 h, pCD-HC was intramuscularly injected subcutaneously